Search
ChatPaper
AI Writing
analysis
Analysis
编组
Open Data
more
More
RankingsMust ReadingJournal&ConferenceAI TRAI HistoryMaster Reading TreeXiaomai's Star TalentsTrajectoryTalentNDI TrackerAI sign LanguageOpen
VIPCreated with Sketch.

Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes.

Vanita R Aroda,Umut Erhan, Peter Jelnes,Juris J Meier,Morten Tind Abildlund,Richard Pratley,Tina Vilsbøll,Mansoor Husain

Diabetes, obesity & metabolism（2023）

Cited 5|Views21
No score
Abstract
The most common AEs with semaglutide were gastrointestinal disorders, which decreased with continued therapy. These comprehensive safety/tolerability data may better inform patient selection and guidance in care.
More
Translated text
Key words
GLP-1,antidiabetic drug,phase III study,randomized trial,type 2 diabetes
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined